
-
Evelo Biosciences Inc OTC Markets OTCPK:EVLO Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Location: 620 Memorial Drive, Cambridge, MA, 02139, United States | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
16.69M
Cash
17.26M
Avg Qtr Burn
-18.43M
Short % of Float
1.05%
Insider Ownership
0.14%
Institutional Own.
11.44%
Qtr Updated
09/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EDP1815 Details COVID-19 | Failed Discontinued | |
EDP1815 Details Atopic dermatitis | Failed Discontinued | |
EDP2939 Details Psoriasis | Failed Discontinued | |
EDP1815 Details Psoriasis | Failed Discontinued | |
EDP1867 Details Atopic dermatitis | Failed Discontinued |